Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 658.00
Bid: 658.00
Ask: 626.00
Change: -15.50 (-2.30%)
Spread: -32.00 (-4.863%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 673.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

31 Mar 2011 07:00

null

31 March 2011 - Tate & Lyle PLC

STATEMENT ON ENTERING CLOSE PERIOD

In line with our usual practice, Tate & Lyle PLC issues the following update for the year ended 31 March 2011 ahead of the announcement of the full year results on 27 May 2011.

OPERATING PERFORMANCE - CONTINUING OPERATIONS

The Group continued its encouraging performance through the year with operating performance similar to market expectations, except that corn price rises drove a further increase in co-product income in the final quarter.

We have continued to deliver global volume growth in Speciality Food Ingredients across all the major product categories through the year. Within Bulk Ingredients, sweetener volumes remained strong and margins improved in industrial starches, particularly in Europe where the market has tightened following a poor potato harvest. The higher co-product income primarily benefits the Bulk Ingredients division.

SALE OF FORT DODGE

On 30 March 2011 we sold our ethanol facility at Fort Dodge, Iowa to Cargill for a cash consideration of US$57 million (£36 million). Following the impairment taken in the year to 31 March 2010, which took the book value of the facility to £17 million, and after additional costs of approximately £3 million, the sale leads to an accounting gain on disposal of around £16 million. Additionally, £20 million of the £25 million exceptional charge booked in the first half of the current financial year in respect of long term contracts relating to the facility will be reversed. Thus we expect an exceptional credit of £36 million in the second half of the current financial year and an exceptional credit for the full year of £11 million. The sale crystallises tax losses of around £65 million, the bulk of which we expect to recover in cash over the coming two financial years; the reported tax rate will not change as a result of the sale as a deferred tax asset was booked at the time of the impairment charge.

BALANCE SHEET

As discussed at the half year results and again at the Interim Management Statement in February, working capital demands on the business have been increased by our decision to keep our US silos full in response to the anticipated tight supply situation running up to the next harvest. In February, we expected that net debt at 31 March 2011 would be at a similar level to that reported at 30 September 2010. With the sale of Fort Dodge, accordingly we now expect the year end net debt to be lower.

END

A conference call will be held today at 8.00am GMT, hosted by Javed Ahmed, Chief Executive and Tim Lodge, Chief Financial Officer. Participants are requested to dial in at least 5 minutes before the commencement of the call. Dial in details are as follows:

Participant dial in number: +44 (0) 1452 555 566Conference ID: 54273374

A replay of this call will be available from two hours after the end of the live call until 6 April 2011.

Replay dial in number: +44 (0) 1452 55 00 00Replay passcode: 54273374#

For more information contact Tate & Lyle PLC:

Chris McLeish, Group VP, Investor and Media RelationsTel: +44 (0) 20 7977 6211 or Mobile: +44 (0) 7919 102 730

Andrew Lorenz or Nick Hasell (Financial Dynamics), Media RelationsTel: +44 (0) 20 7269 7291

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, operating from more than 30 production facilities around the world. Through our large-scale, efficient manufacturing plants, we turn raw materials into distinctive, high quality ingredients for our customers. Our ingredients and solutions add taste, texture, nutrition and increased functionality to products that millions of people around the world use or consume every day.

Tate & Lyle's range of leading branded food ingredients includes SPLENDA® Sucralose, PROMITOR™ Dietary Fiber and STA-LITE® Polydextrose. Tate & Lyle also produces branded industrial ingredients including Bio-PDO™, Ethylex® and Sta-Lok® paper starches; and staple ingredients such as high fructose corn syrup, ethanol, citric acid and basic starches. In addition to providing a wide range of ingredients our Innovation and Commercial Development Group supports customers by providing product development, technical advice and proprietary consumer insight studies.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2010, Tate & Lyle employed 5,666 people in its subsidiaries and joint ventures, and sales totalled £3.50 billion. http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC

Copyright Business Wire 2011

Date   Source Headline
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company
14th May 20243:30 pmRNSHolding(s) in Company
13th May 202410:00 amRNSHolding(s) in Company
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.